Skip to main content
OpenTrials

Clinical trial condition

Chromosome 17 deletion

Explore clinical trials studying Chromosome 17 deletion. Study availability and eligibility vary by location and protocol.

20 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Chromosome 17 deletion trial results

Recruiting

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

NCT07342478

Conditions
CLL, CLL (Chronic Lymphocytic Leukemia), CLL / SLL, +23 more
Locations
  • The Center for Cancer and Blood Disorders-Bethesda Bethesda, Maryland, United States
  • Optum Medical Group (Rhodes) P.C. Las Vegas, Nevada, United States
  • OSU Comprehensive Cancer Center Columbus, Ohio, United States
  • UPMC Hillman Cancer Center Pittsburgh, Pennsylvania, United States
View Trial Details
Recruiting

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT02966756

Conditions
Chromosome 17 deletion, Chronic Disease, Chronic Lymphocytic Leukemia (CLL), +16 more
Locations
  • Concord Repatriation General Hospital /ID# 201261 Concord, New South Wales, Australia
  • St George Hospital /ID# 206484 Kogarah, New South Wales, Australia
  • Monash Health - Monash Medical Centre /ID# 201263 Clayton, Victoria, Australia
  • Anhui Provincial Cancer Hospital /ID# 209458 Hefei, Anhui, China
View all 31 locations
View Trial Details
Completed

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

NCT02633059

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chromosome 17 deletion, +15 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
View Trial Details
Completed

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

NCT03406156

Conditions
Chromosome 17 deletion, Chronic Disease, Chronic Lymphocytic Leukemia (CLL), +17 more
Locations
  • Arizona Oncology Associates, PC-HOPE /ID# 202335 Tempe, Arizona, United States
  • Rocky Mountain Cancer Centers - Denver Midtown /ID# 202328 Denver, Colorado, United States
  • MidAmerica Division, Inc. /ID# 201099 Kansas City, Missouri, United States
  • Oncology Hematology Care, Inc. /ID# 202397 Cincinnati, Ohio, United States
View all 15 locations
View Trial Details

Related conditions